Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic

SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada

Authors: Hannah Chung MPH[1], Siyi He MSc[1], Sharifa Nasreen PhD[1], Maria E. Sundaram

PhD[1,2], Sarah A. Buchan PhD[1,2,3,4], Sarah E. Wilson MD MSc[1,2,3,4], Branson Chen MSc[1],

Andrew Calzavara MSc[1], Deshayne B. Fell PhD[1,5,6], Peter C. Austin PhD[1,7], Kumanan Wilson

MD MSc[8], Kevin L. Schwartz MD MSc[1,2,3], Kevin A. Brown PhD[1,2,3], Jonathan B. Gubbay MD

MSc[3], Nicole E. Basta PhD[9], Salaheddin M. Mahmud MD PhD[10], Christiaan H. Righolt PhD[10],

Lawrence W. Svenson PhD[11,12,13,14], Shannon E. MacDonald PhD[13,15], Naveed Z. Janjua

DrPH[16,17], Mina Tadrous PharmD PhD[1,18], and Jeffrey C. Kwong MD MSc[1,2,3,4,19,20] on behalf of

the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN)

Investigators

Affiliations:

[1] ICES, Toronto, ON

[2] Dalla Lana School of Public Health, University of Toronto, Toronto, ON

[3] Public Health Ontario, ON

[4] Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON

[5] School of Epidemiology and Public Health, University of Ottawa, ON

[6] Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON

[7] Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON

[8] Department of Medicine, University of Ottawa, Ottawa and Bruyere Hospital Research

Institutes, Ottawa, ON

[9] Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and

Global Health, McGill University, Montreal, QC

[10] Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University

of Manitoba, Winnipeg, MB

[11] Analytics and Performance Reporting Branch, Alberta Health, Edmonton, AB

[12] Division of Preventive Medicine, Faculty of Medicine and Dentistry, University of Alberta,

Edmonton, AB

[13] School of Public Health, University of Alberta, Edmonton, AB

[14] Department of Community Health Sciences, Cumming School of Medicine, University of

Calgary, Calgary, AB

[15] Faculty of Nursing, University of Alberta, Edmonton, AB

[16] British Columbia Centre for Disease Control, Vancouver, BC

[17] School of Population and Public Health, University of British Columbia, Vancouver, BC

[18] Women's College Hospital, Toronto, ON

[19] Department of Family and Community Medicine, University of Toronto, Toronto, ON

[20] University Health Network, Toronto, ON

Corresponding author:

Jeff Kwong

Senior Scientist, ICES

G1 06, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5

jeff.kwong@utoronto.ca

Phone: (416) 480-4055 x1-7665

Fax: (416) 480-6048

Abstract word count: 300

Manuscript word count: 2992

Tables/Figures: 5

References: 29

ABSTRACT:

Objectives: To estimate the effectiveness of one and two doses of mRNA COVID-19 vaccines

against symptomatic infection and severe outcomes.

Design: Using a test-negative design study and linked laboratory, vaccination, and health

administrative databases, we estimated adjusted vaccine effectiveness (aVE) against

symptomatic infection and severe outcomes (hospitalization or death) using multivariable

logistic regression.

Setting: Ontario, Canada between 14 December 2020 and 19 April 2021.

Participants: Community-dwelling adults aged ≥16 years who were tested for SARS-CoV-2

and had COVID-19 symptoms.

Interventions: Pfizer-BioNTech's BNT162b2 or Moderna's mRNA-1273 vaccine.

Main outcome measures: Laboratory-confirmed SARS-CoV-2 identified by RT-PCR;

hospitalization or death associated with SARS-CoV-2 infection.

Results: Among 324,033 symptomatic individuals, 53,270 (16.4%) were positive for SARS-

CoV-2 and 21,272 (6.6%) received ≥1 vaccine dose. Among test-positive cases, 2,479 (4.7%)

had a severe outcome. aVE against symptomatic infection ≥14 days after receiving only 1 dose

was 60% (95%CI, 57 to 64%), increasing from 48% (95%CI, 41 to 54%) at 14–20 days after the

first dose to 71% (95%CI, 63 to 78%) at 35–41 days. aVE ≥7 days after receiving 2 doses was

91% (95%CI, 89 to 93%). Against severe outcomes, aVE ≥14 days after receiving 1 dose was

70% (95%CI, 60 to 77%), increasing from 62% (95%CI, 44 to 75%) at 14–20 days to 91%

(95%CI, 73 to 97%) at ≥35 days, whereas aVE ≥7 days after receiving 2 doses was 98% (95%CI,

88 to 100%). For adults aged ≥70 years, aVE estimates were lower after receiving 1 dose, but

were comparable to younger adults after 28 days. After 2 doses, we observed high aVE against

E484K-positive variants.

Conclusions: Two doses of BNT162b2 and mRNA-1273 vaccines are highly effective against

both symptomatic infection and severe outcomes. Effectiveness is lower after only a single dose,

particularly for older adults shortly after the first dose.

INTRODUCTION

Understanding how clinical trial efficacy estimates of COVID-19 vaccines translate into real-

world effectiveness estimates is crucial, given differences in populations, dosing intervals, and

emerging variants.[1] Due to COVID-19 vaccine supply constraints, Canada's National Advisory

Committee on Immunization (NACI) recommended extending the interval between doses to a

maximum of 16 weeks.[2] With vaccine supply constraints globally, determining the effectiveness

of these vaccines following a single dose vs. two doses is important for informing policy for

many countries.[1]

We applied the test-negative design to linked, population-based health databases in

Ontario, Canada (population 15 million) to evaluate vaccine effectiveness (VE) against

symptomatic SARS-CoV-2 infection and severe outcomes (i.e., hospitalization or death

associated with SARS-CoV-2 infection) for two mRNA vaccines (Pfizer-BioNTech's

BNT162b2 and Moderna's mRNA-1273).

METHODS

Study population, setting, and design

We conducted a test-negative design study among community-dwelling Ontarians who had

symptoms consistent with COVID-19. The test-negative design is comparable to a nested case-

control design, with symptomatic individuals who are tested for the presence of a pathogen of

interest serving as the nesting cohort.[1,3,4] All Ontarians aged ≥16 years, eligible for provincial

health insurance, not living in long-term care, and who were tested for SARS-CoV-2 between 14

December 2020 and 19 April 2021 were eligible for inclusion. We excluded individuals who

tested positive for SARS-CoV-2 prior to 14 December 2020 and recipients of the ChAdOx1

vaccine. We restricted the analysis to individuals who were documented to have at least one

relevant COVID-19 symptom at the time of testing.

Data sources and definitions

We linked data from provincial SARS-CoV-2 laboratory testing, COVID-19 vaccination, and

health administrative datasets using unique encoded identifiers and analyzed them at ICES.

Outcomes

Our first primary outcome of interest was symptomatic SARS-CoV-2 infection, ascertained by

real-time reverse transcription polymerase chain reaction (RT-PCR).[5] Using data from the

Ontario Laboratories Information System (OLIS), which captured 91.8% (n=258,207) of all

provincially reported cases of laboratory-confirmed COVID-19 (n=281,261) during the study

period, test-positive individuals were treated as cases and test-negative individuals were treated

as controls. Since symptom onset dates were inconsistently reported in OLIS, we used the

specimen collection date as the index date. For cases with multiple positive tests, we used the

date of their first positive test. For controls with multiple negative tests, we used the date of a

randomly selected negative test as the index date.

We obtained information on variants and mutations from the Public Health Case and Contact

Management system (CCM), which contains information on the clinical course of cases and the

results of screening tests for N501Y and E484K mutations and whole genome sequencing results

that identify specific variant of concern (VOC) lineages (B.1.1.7, B.1.351, P.1). All RT-PCR-

positive specimens with cycle threshold values ≤35 were tested for the N501Y mutation (starting

3 February 2021) and the E484K mutation (starting 22 March 2021).[6] We considered samples

with positive N501Y and negative E484K mutations as lineage B.1.1.7, and samples with

positive N501Y and E484K mutations as lineage B.1.351 or P.1. We combined the latter two

lineages for our analysis because there were very small numbers of cases identified using whole

genome sequencing.

Our second primary outcome was severe disease associated with SARS-CoV-2 infection, defined

as either hospitalization or death with a recent positive test, using the earliest of the specimen

collection date or the hospitalization or death date as the index date. We identified these

outcomes using CCM (for both hospitalizations and deaths), the Canadian Institute for Health

Information's Discharge Abstract Database (DAD; for hospitalizations), and the Ontario

Registered Persons Database (RPDB; for deaths). For hospitalizations identified using DAD, a

positive test must have occurred within 14 days prior to or 3 days after admission. For deaths

identified using RPDB, a positive test must have occurred within 30 days prior to death or within

7 days post-mortem.

COVID-19 vaccination

BNT162b2 became available in Ontario on 14 December 2020, and mRNA-1273 on 28

December 2020.[7] The initial vaccination phase prioritized high-risk populations such as older

adults living in congregate settings, healthcare workers, adults living in Indigenous communities,

and adults aged ≥80 years. Ontario had initially followed the manufacturers' recommended

dosing schedules (i.e., a 21-day interval for BNT162b2 and a 28-day interval for mRNA-1273),

but in late January 2021 extended the interval to 35-42 days for everyone except older adults

living in congregate settings and Indigenous individuals, due to disruptions in vaccine supply. In

early March, Ontario adopted NACI's recommendation to delay administration of the second

dose by up to 16 weeks for most individuals.[8,9] By April, eligibility was expanded to include

adults in high COVID-19-incidence communities, individuals with certain health conditions and

their caregivers, certain essential frontline workers, and graduated expansion of eligibility by

decreasing age.[7] As of 19 April 2021, 28% of Ontario adults had received at least one dose of a

COVID-19 vaccine.[10] Comprehensive documentation of all COVID-19 vaccination events in

Ontario, including product, date of administration, and dose number, is recorded in COVaxON, a

centralized COVID-19 vaccine information system.

Covariates

We obtained age, sex, and postal code of residence as of 14 December 2020 from RPDB. We

obtained the number of RT-PCR tests for each subject during the 3 months prior to 14 December

2020 from OLIS to use as a proxy for highly tested individuals at increased risk of exposure to

SARS-CoV-2 infection (e.g., healthcare workers and caregivers of long-term care residents, who

must also undergo serial SARS-CoV-2 testing). We grouped testing dates into 2-week periods to

capture temporal changes in viral activity and regional vaccine roll-out. We determined the

presence of comorbidities that increase the risk of severe COVID-19,[11] identified from various

databases using validated algorithms and commonly accepted diagnostic codes, which have been

described elsewhere.[12] We ascertained receipt of influenza vaccination during the 2019/2020

and/or 2020/2021 influenza season using physician and pharmacist billing claims in the Ontario

Health Insurance Plan and Ontario Drug Benefit databases, respectively. We determined the

public health unit of residence using the postal code and Statistics Canada Postal Code

Conversion File Plus (version 7B) and grouped them into larger regions. We obtained

information at the ecologic level of dissemination area (DA) on four important social

determinants of health (median neighbourhood income, proportion of the working population

employed as non-health essential workers [i.e., those unable to work from home], average

number of persons per dwelling, and proportion of the population who self-identify as a visible

minority) from 2016 Census data.[13] DAs generally contain 400-700 individuals. Details related

to these covariates are available in **Supplementary Table S1**.

Statistical analysis

We conducted descriptive analyses and calculated standardized differences to compare

characteristics between test-positive cases and test-negative controls, and between vaccinated

and unvaccinated individuals.

We used multivariable logistic regression models to estimate the odds ratio (OR) comparing the

odds of vaccination between test-positive cases and test-negative controls. We estimated

unadjusted and adjusted odds ratios accounting for all covariates listed above. These covariates

were selected *a priori* based on their known associations with SARS-CoV-2 infection or severity

and COVID-19 vaccine receipt.[2,11,14] VE was calculated using the following formula: VE = (1-

OR) x 100%.

For the primary analysis, we estimated overall VE (for both vaccines combined) for those who

received only 1 dose by their index date and those who received 2 doses by their index date. We

considered index dates within varying intervals after vaccination.

We also estimated VE ≥14 days after the first dose (among those who only received 1 dose) and

≥7 days after the second dose, stratified by vaccine product (BNT162b2 or mRNA-1273), age

group (16–39, 40–69, and ≥70 years), sex, presence of any comorbidity, epidemic wave (index

dates 14 December 2020–7 February 2021, representing wave 2 in Ontario; 8 February 2021–21

March 2021, representing the period between wave 2 and wave 3; and 22 March 2021–19 April

2021, representing wave 3), and variant (earlier variant vs. B.1.1.7 vs. B.1.351 or P.1). We also

estimated VE by varying intervals after vaccination stratified by age group.

We repeated these analyses for severe outcomes, with adjustments to the intervals after

vaccination due to reduced sample sizes.

All analyses were conducted using SAS Version 9.4 (SAS Institute Inc., Cary, NC). All tests

were two-sided and used $p<0.05$ as the level of statistical significance.

RESULTS

From 14 December 2020 – 19 April 2021, 2,171,449 individuals were tested for SARS-CoV-2.

After excluding individuals who had SARS-CoV-2 infection prior to the study period and

individuals who had received ChAdOx1 vaccine, 60.5% of those remaining did not have

symptoms consistent with COVID-19 or had no symptom information recorded in OLIS, 24.4%

were recorded as asymptomatic, and 15.1% had symptoms consistent with COVID-19 recorded

at the time of testing (**eFigure 1**). Grouped together, individuals with COVID-19-like symptoms

and those deemed asymptomatic had similar characteristics as the remaining individuals, except

for COVID-19 vaccine uptake, public health unit region, and number of previous SARS-CoV-2

tests (**eTable 2**). Of the 324,033 symptomatic tested individuals, 53,270 (16.4%) tested positive

for SARS-CoV-2 and 21,272 (6.6%) had received ≥1 dose of mRNA vaccine. Among test-

positive cases, 2,479 (4.7%) were hospitalized or died.

Test-positive cases were more likely to be male; more likely to reside in Peel Region or Toronto;

more likely to have had zero SARS-CoV-2 tests during the 3 months prior to the vaccination

program; less likely to have received an influenza vaccine; and more likely to reside in

neighbourhoods with lower income, more persons per dwelling, and greater proportions of

essential workers and visible minorities (**Table 1**). Vaccinated individuals were older; less likely

to be male; more likely to have had multiple SARS-CoV-2 tests during the 3 months prior to the

vaccination program; more likely to have a comorbidity; and more likely to have received an

influenza vaccine. Compared to recipients of mRNA-1273 vaccine, recipients of BNT162b2

vaccine were younger, more likely to be female, and less likely to have a comorbidity (**eTable**

3). Most individuals (77% for BNT162b2, 76% for mRNA-1273) had received only 1 dose by

the index date.

Against symptomatic infection, adjusted VE (aVE) ≥14 days after receiving only 1 dose was

60% (95%CI, 57–64%). This increased from 48% (95%CI, 41–54%) at 14–20 days to a plateau

of 71% (95%CI, 63–78%) at 35–41 days (**Figure 1, eTable 4**). We observed a 16% increase in

risk of symptomatic infection 7-13 days after a first dose (aVE -16%; 95%CI, -26% to -6%).

aVE ≥7 days after receiving 2 doses was 91% (95%CI, 89–93%). Against severe outcomes of

hospitalization or death, aVE ≥14 days after receiving 1 dose was 70% (95%CI, 60–77%),

increasing from 62% (95%CI, 44–75%) at 14–20 days to 91% (95%CI, 73–97%) at ≥35 days,

whereas aVE ≥7 days after receiving 2 doses was 98% (95%CI, 88–100%) (**Figure 2, eTable 4**).

In subgroup analyses of VE against symptomatic infection, we observed higher aVE ≥14 days

after receiving only 1 dose with mRNA-1273 than BNT162b2, for younger adults than adults

aged ≥70 years, for individuals with no comorbidities than for those with comorbidities, and

against the earlier variant and B.1.1.7 than B.1.351 or P.1 (though 95% confidence intervals for

aVE for variants overlapped) (**Figure 3a, eTable 5**). However, aVE estimates ≥7 days after

receiving 2 doses were high (all ≥88%) and comparable across all subgroups, including against

E484K-positive variants. Against severe outcomes, we observed higher aVE ≥14 days after

receiving 1 dose for younger adults aged 16-39 years, but aVE estimates ≥0 days after receiving

2 doses were mostly similar across subgroups (**Figure 3b, eTable 6**).

Among adults ≥70 years, VE against symptomatic infection after 1 dose increased to 64%

(95%CI 46–76%) at 28–34 days and 85% (95%CI 38–97%) at 42–48 days, whereas comparable

VE estimates were achieved sooner after 1 dose for younger adults (**Figure 4, eTable 7**). For

older adults, VE against severe outcomes was comparable at ≥35 days after 1 dose (93%;

95%CI, 71–98%) as after receiving 2 doses (97%; 95%CI, 86–99%).

DISCUSSION

We estimated very high (>90%) vaccine effectiveness of mRNA vaccines BNT162b2 and

mRNA-1273 against symptomatic SARS-CoV-2 infection with full vaccination (i.e., ≥7 days

after receipt of a second dose), and moderate (~50-70%) VE with partial vaccination (i.e., ≥14

days after receipt of only a first dose). Estimates for both full and partial vaccination were

approximately 10% higher against hospitalization or death, and VE increased over time after a

first dose. In subgroup analyses, we observed lower VE against symptomatic infection after a

first dose for recipients of BNT162b2, adults aged ≥70 years, and individuals with comorbidities.

However, VE was consistently high across subgroups for fully vaccinated individuals, and also

for older adults after longer intervals following receipt of a first dose. We also noted a slightly

increased risk of symptomatic infection on days 7-13 after a first dose, compared to no

vaccination.

Our findings for fully vaccinated individuals are comparable with clinical trial efficacy estimates

and other real-world effectiveness estimates reported in a range of settings.[15-25] Existing evidence

estimating one-dose effectiveness from observational studies is heterogeneous,[20,22,24-26] with

estimates for symptomatic infection ranging from 57% (95%CI, 50–63%)[22] to 72% (95%CI, 58–

86%)[25] and post-hoc calculations from efficacy trials approximately 90%.[27,28] There is similar

heterogeneity among one-dose effectiveness estimates in older adults,[18,26,29] with estimates

generally lower for older adults after the first dose,[22,26] and increasing with time. Our analysis

identified an effectiveness against symptomatic infection of 63% (95%CI, 40–72%) ≥49 days

after only the first dose, in keeping with several other studies reporting one-dose

effectiveness.[22,24] Our analysis also reflects extant evidence that effectiveness increases to very

high levels after the second dose, including in older adults.[22] Our finding that receipt of 2 doses

of mRNA vaccines was not associated with appreciable vaccine escape by lineage B.1.1.7 or

E484K-positive variants (i.e., B.1.351 and P.1) is notable.

The increased risk of infection 7-13 days after receiving the vaccine could be due to an increase

in SARS-CoV-2 exposures shortly prior to, during, or after vaccination. Individuals may be

incubating at the time of vaccination, they may be exposed due to inadequate infection

prevention and control measures at (or when travelling to/from) vaccination clinics, or they may

assume protection immediately following vaccination and engage in higher risk behaviours

before a sufficient immune response has developed. Future studies should evaluate the

effectiveness of infection prevention and control measures in vaccination clinics and examine the

potential role of behavioural changes post first dose of COVID-19 vaccines.

Our study had some limitations. First, our study sample was limited to those with COVID-19

symptoms recorded in OLIS. Not all laboratories in Ontario currently have the information

technology infrastructure to submit symptom information recorded on the SARS-CoV-2

laboratory requisition into OLIS. Thus, the generalizability of our findings to the broader

population is uncertain. In addition, COVID-19 vaccination status is now collected on the

laboratory requisition. This may introduce selection bias and underestimate the true VE estimate

if symptoms were more likely to be documented on requisition forms for vaccinated individuals

who ultimately test positive for SARS-CoV-2, for example. Traditional test-negative design

studies collect vaccination status among all individuals with symptoms consistent with the

pathogen under study, to minimize this selection bias. However, the congruence of our findings

for fully vaccinated individuals with extant studies provides some reassurance that any under- or

overestimation of VE is likely to be small. Second, because symptom onset date is largely

unavailable in OLIS and CCM only has information on test-positive cases, we used specimen

collection date as the index date. This may have led to classifying some individuals into an

incorrect dose-to-index date interval, because their symptom onset would have been several days

prior to getting tested, leading to underestimation of VE during earlier intervals. Furthermore, we

could not limit the study population to individuals tested within 10 days of symptom onset, a

commonly used inclusion criterion for test-negative studies. Prolonging the interval between

symptom onset and testing increases the likelihood of false-negative cases, which lowers VE

estimates. However, 89% of cases with both symptom onset and specimen collection date

documented in CCM (not the source of symptom data for this study) were tested within 10 days

of symptom onset. Third, our results may have been impacted by outcome misclassification of

severe outcomes due to unlinked case records and incomplete capture of severe outcomes in

CCM, and delays in identifying hospitalizations in DAD (which are dependent on individuals

being discharged) and deaths in RPDB. Fourth, some of our covariates may be subject to

measurement error. We used frequency of previous SARS-CoV-2 tests as a proxy to identify

individuals at higher risk of exposure (and increased likelihood to be targeted for early

vaccination). However, we did not include point-of-care tests because they are incompletely

captured in OLIS. Furthermore, since access to testing is variable, we might not have adequately

controlled for this concept. Finally, we may not have adequately accounted for confounding bias

with the covariates that were available in the study databases.

Our findings suggest that older individuals and those with comorbidities may benefit from risk-

based recommendations to minimize second-dose delays. However, rising protection against

severe outcomes – arguably the more important outcome – with increasing time after a first dose

provides support for delaying the second dose. Mathematical modelling could be conducted to

demonstrate how, particularly for jurisdictions with limited vaccine supply, vaccines should be

distributed to maximize population protection (e.g., the relative benefits of providing second

doses earlier to older populations versus providing more first doses to younger populations who

respond better to a single dose and leading to more rapid achievement of herd immunity by

maximizing coverage with 1 dose). Since VE against symptomatic infection after 1 dose is only

moderate, and among older adults appears to be modest even at 14–20 days, individuals need to

be informed that besides the absence of benefit during the first 2 weeks (and likely longer for

older adults) after a first dose, they should continue to adhere to recommended public health

measures, such as mask-wearing, physical distancing, and avoidance of social gatherings.

<u>Conflicts of interest</u>

KW is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19

vaccine trial. SMM has received unrestricted research grants from Merck, GlaxoSmithKline,

Sanofi Pasteur, Pfizer, and Roche-Assurex for unrelated studies. SMM has received fees as an

advisory board member for GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, and Seqirus. CHR

has received an unrestricted research grant from Pfizer for an unrelated study. The other authors

declare no conflicts of interest.

<u>Contributors</u>

HC and JCK designed and oversaw the study. SH and HC obtained the data and conducted all

analyses (data set and variable creation and statistical modelling). BC contributed to data

analyses and data preparation for the symptomatic data set. SN, MES, HC, and JCK drafted the

manuscript. All authors contributed to the analysis plan, interpreted the results, critically

reviewed and edited the manuscript, approved the final version, and agreed to be accountable for

all aspects of the work.

<u>Ethics approval</u>

ICES is a prescribed entity under Ontario's Personal Health Information Protection Act

(PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without

consent, for the purpose of analysis or compiling statistical information with respect to the

management of, evaluation or monitoring of, the allocation of resources to or planning for all or

part of the health system. Projects that use data collected by ICES under section 45 of PHIPA,

and use no other data, are exempt from REB review. The use of the data in this project is

authorized under section 45 and approved by ICES' Privacy and Legal Office.

<u>Funding</u>

This work was supported by the Canadian Immunization Research Network (CIRN) through a

grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research

(CNF 151944). This project was also supported by funding from the Public Health Agency of

Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task

Force. This study was also supported by ICES, which is funded by an annual grant from the

Ontario Ministry of Health (MOH). JCK is supported by Clinician-Scientist Award from the

University of Toronto Department of Family and Community Medicine. PCA is supported by a

Mid-Career Investigator Award from the Heart and Stroke Foundation.

<u>Data availability statement</u>

The dataset from this study is held securely in coded form at ICES. While legal data sharing

agreements between ICES and data providers (e.g., healthcare organizations and government)

prohibit ICES from making the dataset publicly available, access may be granted to those who

meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email:

das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from

the authors upon request, understanding that the computer programs may rely upon coding

templates or macros that are unique to ICES and are therefore either inaccessible or may require

modification.

<u>Acknowledgments</u>

We would like to acknowledge Public Health Ontario for access to case-level data from CCM

and COVID-19 laboratory data, as well as assistance with data interpretation. We also thank the

staff of Ontario's public health units who are responsible for COVID-19 case and contact

management and data collection within CCM. We thank IQVIA Solutions Canada Inc. for use of

their Drug Information Database. The authors are grateful to the Ontario residents without whom

this research would be impossible.

<u>Disclaimers</u>

This study was supported by ICES, which is funded by an annual grant from the Ontario

Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study was

supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to

support Ontario's ongoing response to COVID-19 and its related impacts. The study sponsors

did not participate in the design and conduct of the study; collection, management, analysis and

interpretation of the data; preparation, review or approval of the manuscript; or the decision to

submit the manuscript for publication. Parts of this material are based on data and/or information

compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer

Care Ontario (CCO). However, the analyses, conclusions, opinions and statement expressed

herein are solely those of the authors, and do not reflect those of the funding or data sources; no

endorsement by ICES, MOH, MLTC, OHDP, its partners, the Province of Ontario, CIHI or CCO

is intended or should be inferred.

References

1. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. *JAMA.* 2020.

2. National Advisory Committee on Immunization. Guidance on the prioritization of key populations for COVID-19 immunization. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-prioritization-key-populations-covid-19-vaccination.html. Published 2021. Updated February 12, 2021. Accessed May 2, 2021.

3. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine.* 2013;31(17):2165-2168.

4. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. *American journal of epidemiology.* 2016;184(5):345-353.

5. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. *BMJ.* 2020;369:m1808.

6. Updates to PHO's Variants of Concern Laboratory Testing. Public Health Ontario. https://www.publichealthontario.ca/en/about/blog/2021/lab-voc-testing-updates. Published 2021. Updated March 25, 2021. Accessed May 3, 2021.

7. Ontario's COVID-19 vaccination plan. Ontario Ministry of Health. https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan#our-three-phased-vaccination-plan. Published 2021. Updated April 30, 2021. Accessed May 3, 2021.

8. *Vaccine Clinical Advisory Group (VCAG) Recommendations on Exceptions to Extended Dose Intervals for COVID-19 Vaccines.* Ontario: Ontario Ministry of Health; March 26, 2021 2021.

9. *Extension of the Second Dose Interval.* Ontario: Ontario Ministry of Health; Updated April 23, 2021 2021.

10. ICES COVID-19 Dashboard. ICES. https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard. Published 2021. Accessed May 3, 2021.

11. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. US Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Published 2021. Updated April 30, 2021. Accessed May 3, 2021.

12. Kwong JC, Buchan SA, Chung H, et al. Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. *Vaccine.* 2019;37(31):4392-4400.

13. Statistics Canada/Statistique Canada. Dictionary, Census of Population, 2016. https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/geo021-eng.cfm. Published 2020. Accessed October 13, 2020.

14. Sundaram ME, Calzavara A, Mishra S, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. *CMAJ.* 2021.

15. Vahidy FS, Pischel L, Tano ME, et al. Real world effectiveness of COVID-19 mRNA vaccines against hospitalizations and deaths in the United States. *medRxiv.* 2021.

16. Mason T, Whitston M, Hodgson J, et al. Effects of BNT162b2 mRNA vaccine on Covid-
19 infection and hospitalisation among older people: matched case control study for
England. *medRxiv*. 2021.
17. Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F.
Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age
population — first results from a cohort study in Southern Sweden. *medRxiv*. 2021.
18. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination
with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on
symptomatic disease, hospitalisations and mortality in older adults in England. *medRxiv*.
2021.
19. Pawlowski C, Lenehan P, Puranik A, et al. FDA-authorized COVID-19 vaccines are
effective per real-world evidence synthesized across a multi-state health system.
medRxiv. 2021.
20. Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using
aggregated counts. *medRxiv*. 2021.
21. Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine
effectiveness with patient age and comorbidities. *medRxiv*. 2021.
22. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a
Nationwide Mass Vaccination Setting. *The New England journal of medicine*. 2021.
23. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first dose of COVID-19
vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4
million people. *SSRN (pre-print server)*. 2021.
24. Andrejko K, Pry J, Myers JF, et al. Early evidence of COVID-19 vaccine effectiveness
within the general population of California. *medRxiv*. 2021.
25. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in
England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
prospective, multicentre, cohort study. *The Lancet*. 2021;397(10286):1725-1735.
26. Chodick G, Tene L, Patalon T, et al. The effectiveness of the first dose of BNT162b2
vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world
evidence. *medRxiv*. 2021.
27. Skowronski DM, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19
Vaccine: Letter to the Editor. *The New England journal of medicine*. 2021;384(16):1576-
1577.
28. *Annex A: Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech
(BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222)*. UK:
Public Health England; December 22 2020.
29. Hyams C, Marlow R, Maseko Z, et al. Assessing the effectiveness of BNT162b2 and
ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly
and frail adults: a single centre test negative case-control study. *SSRN (pre-print server)*.
2021.
494

Table 1. Characteristics of symptomatic individuals tested for SARS-CoV-2 between 14 December 2020 and 19 April 2021 in Ontario, Canada.

Characteristic	SARS-CoV-2-positive, n (%)[a] (N=53,270)	SARS-CoV-2-negative, n (%)[a] (N=270,763)	Standardized difference[b]	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%)[a] (N=21,272)	Unvaccinated, n (%)[a] (N=302,761)	Standardized difference[b]
Received ≥1 dose of COVID-19 vaccine	2,050 (3.8)	19,222 (7.1)	-	-	-	-
Received 2 doses of COVID-19 vaccine	73 (0.1)	4,821 (1.8)	-	-	-	-
Tested positive for SARS-CoV-2	-	-	-	2,050 (9.6)	51,220 (16.9)	-
Earlier variant	-	-	-	579 (2.7)	27,510 (9.1)	-
B.1.1.7	-	-	-	807 (3.8)	12,282 (4.1)	-
B.1.351 or P.1 (E484K+ variants)	-	-	-	98 (0.5)	1,291 (0.4)	-
Age (years), mean (standard deviation)	42.4 (17.1)	43.2 (17.8)	0.04	51.8 (20.8)	42.4 (17.3)	0.49
Age group (years)						
16–29	15,175 (28.5)	72,238 (26.7)	0.04	3,457 (16.3)	83,956 (27.7)	0.28
30–39	10,024 (18.8)	59,326 (21.9)	0.08	4,011 (18.9)	65,339 (21.6)	0.07
40–49	9,642 (18.1)	46,225 (17.1)	0.03	3,287 (15.5)	52,580 (17.4)	0.05
50–59	9,460 (17.8)	40,874 (15.1)	0.07	3,112 (14.6)	47,222 (15.6)	0.03
60–69	5,279 (9.9)	27,342 (10.1)	0.01	2,261 (10.6)	30,360 (10.0)	0.02
70–79	2,426 (4.6)	14,888 (5.5)	0.04	2,272 (10.7)	15,042 (5.0)	0.21
≥80	1,264 (2.4)	9,870 (3.6)	0.07	2,872 (13.5)	8,262 (2.7)	0.40
Male sex	25,993 (48.8)	112,501 (41.5)	0.15	6,013 (28.3)	132,481 (43.8)	0.33
Public health unit region[c]						
Central East	2,624 (4.9)	29,194 (10.8)	0.22	1,969 (9.3)	29,849 (9.9)	0.02
Central West	8,322 (15.6)	48,419 (17.9)	0.06	3,853 (18.1)	52,888 (17.5)	0.02
Durham	1,433 (2.7)	8,583 (3.2)	0.03	522 (2.5)	9,494 (3.1)	0.04
Eastern	689 (1.3)	15,147 (5.6)	0.24	1,087 (5.1)	14,749 (4.9)	0.01
North	1,753 (3.3)	31,321 (11.6)	0.32	2,251 (10.6)	30,823 (10.2)	0.01
Ottawa	417 (0.8)	3,144 (1.2)	0.04	446 (2.1)	3,115 (1.0)	0.09
Peel	13,515 (25.4)	32,981 (12.2)	0.34	2,395 (11.3)	44,101 (14.6)	0.10
South West	7,562 (14.2)	39,316 (14.5)	0.01	3,885 (18.3)	42,993 (14.2)	0.11
Toronto	12,458 (23.4)	45,540 (16.8)	0.16	3,462 (16.3)	54,536 (18.0)	0.05
York	4,278 (8.0)	15,995 (5.9)	0.08	1,323 (6.2)	18,950 (6.3)	0.00
Biweekly period of test						
14 Dec 2020 to 27 Dec 2020	4,139 (7.8)	27,456 (10.1)	0.08	13 (0.1)	31,582 (10.4)	0.48
28 Dec 2020 to 10 Jan 2021	6,870 (12.9)	26,993 (10.0)	0.09	335 (1.6)	33,528 (11.1)	0.40

Characteristic	SARS-CoV-2-positive, n (%)[a] (N=53,270)	SARS-CoV-2-negative, n (%)[a] (N=270,763)	Standardized difference[b]	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%)[a] (N=21,272)	Unvaccinated, n (%)[a] (N=302,761)	Standardized difference[b]
11 Jan 2021 to 24 Jan 2021	4,864 (9.1)	26,747 (9.9)	0.03	1,068 (5.0)	30,543 (10.1)	0.19
25 Jan 2021 to 7 Feb 2021	3,539 (6.6)	24,276 (9.0)	0.09	1,204 (5.7)	26,611 (8.8)	0.12
8 Feb 2021 to 21 Feb 2021	3,595 (6.7)	24,800 (9.2)	0.09	1,031 (4.8)	27,364 (9.0)	0.17
22 Feb 2021 to 7 Mar 2021	3,539 (6.6)	30,760 (11.4)	0.17	1,491 (7.0)	32,808 (10.8)	0.13
8 Mar 2021 to 21 Mar 2021	5,134 (9.6)	32,776 (12.1)	0.08	2,790 (13.1)	35,120 (11.6)	0.05
22 Mar 2021 to 4 Apr 2021	8,338 (15.7)	35,910 (13.3)	0.07	4,814 (22.6)	39,434 (13.0)	0.25
5 Apr 2021 to 19 Apr 2021	13,252 (24.9)	41,045 (15.2)	0.24	8,526 (40.1)	45,771 (15.1)	0.58
Number of tests in previous 3 months						
0	43,713 (82.1)	189,786 (70.1)	0.28	11,588 (54.5)	221,911 (73.3)	0.40
1	7,151 (13.4)	54,827 (20.2)	0.18	4,338 (20.4)	57,640 (19.0)	0.03
≥2	2,406 (4.5)	26,150 (9.7)	0.20	5,346 (25.1)	23,210 (7.7)	0.49
Any comorbidity[d]	23,212 (43.6)	127,974 (47.3)	0.07	12,218 (57.4)	138,968 (45.9)	0.23
Receipt of 2019-2020 and/or 2020-2021 influenza vaccination	13,751 (25.8)	89,395 (33.0)	0.16	9,587 (45.1)	93,559 (30.9)	0.30
Neighbourhood income quintile[c, e]						
1 (lowest)	11,878 (22.3)	47,944 (17.7)	0.11	3,750 (17.6)	56,072 (18.5)	0.02
2	11,154 (20.9)	51,470 (19.0)	0.05	4,146 (19.5)	58,478 (19.3)	0.00
3	11,477 (21.5)	52,628 (19.4)	0.05	4,233 (19.9)	59,872 (19.8)	0.00
4	10,146 (19.0)	56,676 (20.9)	0.05	4,513 (21.2)	62,309 (20.6)	0.02
5 (highest)	8,359 (15.7)	60,774 (22.4)	0.17	4,540 (21.3)	64,593 (21.3)	0.00
Essential workers quintile[c, f]						
1 (0%–32.5%)	6,440 (12.1)	50,664 (18.7)	0.18	3,917 (18.4)	53,187 (17.6)	0.02
2 (32.5%–42.3%)	11,225 (21.1)	60,040 (22.2)	0.03	4,664 (21.9)	66,601 (22.0)	0.00
3 (42.3%–49.8%)	11,106 (20.8)	56,108 (20.7)	0.00	4,468 (21.0)	62,746 (20.7)	0.01
4 (50.0%–57.5%)	11,576 (21.7)	52,849 (19.5)	0.05	4,211 (19.8)	60,214 (19.9)	0.00
5 (57.5%–100%)	12,519 (23.5)	49,067 (18.1)	0.13	3,859 (18.1)	57,727 (19.1)	0.02
Persons per dwelling quintile[c, g]						
1 (0–2.1)	5,781 (10.9)	51,852 (19.2)	0.23	4,277 (20.1)	53,356 (17.6)	0.06
2 (2.2–2.4)	6,641 (12.5)	52,326 (19.3)	0.19	4,219 (19.8)	54,748 (18.1)	0.04
3 (2.5–2.6)	5,633 (10.6)	37,229 (13.7)	0.10	3,020 (14.2)	39,842 (13.2)	0.03
4 (2.7–3.0)	12,967 (24.3)	63,774 (23.6)	0.02	4,874 (22.9)	71,867 (23.7)	0.02

Characteristic	SARS-CoV-2-positive, n (%)[a] (N=53,270)	SARS-CoV-2-negative, n (%)[a] (N=270,763)	Standardized difference[b]	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%)[a] (N=21,272)	Unvaccinated, n (%)[a] (N=302,761)	Standardized difference[b]
5 (3.1–5.7)	21,833 (41.0)	63,459 (23.4)	0.38	4,709 (22.1)	80,583 (26.6)	0.10
Self-identified visible minority quintile[c, h]						
1 (0.0%–2.2%)	4,437 (8.3)	51,919 (19.2)	0.32	4,133 (19.4)	52,223 (17.2)	0.06
2 (2.2%–7.5%)	5,752 (10.8)	55,124 (20.4)	0.27	4,592 (21.6)	56,284 (18.6)	0.07
3 (7.5%–18.7%)	7,223 (13.6)	51,122 (18.9)	0.14	3,982 (18.7)	54,363 (18.0)	0.02
4 (18.7%–43.5%)	10,718 (20.1)	53,691 (19.8)	0.01	3,974 (18.7)	60,435 (20.0)	0.03
5 (43.5%–100%)	24,736 (46.4)	56,876 (21.0)	0.56	4,438 (20.9)	77,174 (25.5)	0.11

[a]Proportion reported, unless stated otherwise.

[b]Standardized differences of >0.10 are considered clinically relevant.

[c]The sum of counts does not equal the column total because of individuals with missing information (<1.0%) for this characteristic.

[d]Comorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

[e]Neighbourhood income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income.

[f]Percentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

[g]Range of persons per dwelling.

[h]Percentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

Figure 1. Unadjusted (panel A) and adjusted[*] (panel B) vaccine effectiveness estimates of COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) against laboratory-confirmed symptomatic SARS-CoV-2 infection by various intervals, between 14 December 2020 and 19 April 2021 in Ontario, Canada.

Figure 2. Unadjusted (panel A) and adjusted[*] (panel B) vaccine effectiveness estimates of COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) against severe outcomes (hospitalization or death) associated with laboratory-confirmed symptomatic SARS-CoV-2 infection by various intervals, between 14 December 2020 and 19 April 2021 in Ontario, Canada.

---

[*] Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles.

Figure 3. Adjusted[*] vaccine effectiveness estimates ≥14 days after Dose 1 (for individuals who received only 1 dose) and ≥0 days after Dose 2 by various factors, including vaccine product, patient characteristics, epidemic wave, and SARS-CoV-2 lineage against laboratory-confirmed symptomatic SARS-CoV-2 infection (panel A) and severe outcomes (hospitalization or death) (panel B) between 14 December 2020 and 19 April 2021.

---

[*] Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles (unless adjusted variable was used for stratification).

□ For subgroup analyses by characteristic and SARS-CoV-2 lineage, individuals vaccinated with either mRNA vaccine was included.

[**]For vaccine effectiveness against symptomatic SARS-CoV-2 infection (panel A), this interval was ≥7 days after Dose 2. However, against serious outcomes (panel B), an alternative interval was selected (≥0 days after Dose 2) because of limited number of outcomes.

Figure 4. Adjusted[*] vaccine effectiveness estimates ≥14 days after Dose 1 and ≥0 days after Dose 2 in community-dwelling adults in Ontario, Canada against laboratory-confirmed symptomatic SARS-CoV-2 infection for adults aged ≥70 years (panel A), 40-69 years (panel B), and 16-39 years (panel C) and severe outcomes (hospitalization or death) for adults aged ≥70 years (panel D) and 40-69 years (panel E), between 14 December 2020 and 19 April 2021.

---

[*] Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income, essential worker, persons per dwelling, proportion of persons employed as non-health essential workers and self-identified visible minority quintiles (unless adjusted variable was used for stratification).

For subgroup analyses by characteristic and SARS-CoV-2 lineage, individuals vaccinated with either mRNA vaccine was included.

**For vaccine effectiveness against symptomatic SARS-CoV-2 infection (panels A, B, and C), this interval was ≥7 days after Dose 2. However, against serious outcomes (panels D and E), an alternative interval was selected (≥0 days after Dose 2) because of limited number of outcomes.